Benefit of TTR-stabilizer starts as early as 3 months in transthyretin amyloid cardiomyopathy - PACE-CME

Benefit of TTRstabilizer starts as early as months in transthyretin amyloid cardiomyopathy

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Results with novel FXI inhibitor in AF set the stage for phase 3 trials
Results with novel FXI inhibitor in AF set the stage for phase 3 trials
AHA 2023
Results with novel FXI inhibitor in AF set the stage for phase 3 trials
- Christian Ruff, MD
An option for lowering BP beyond prescribing an additional pill
An option for lowering BP beyond prescribing an additional pill
AHA 2023
An option for lowering BP beyond prescribing an additional pill
- Florian Rader, MD
GLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications
GLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications
AHA 2023
GLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications
- Michael Lincoff, MD
Novel insights on the importance of dietary sodium reduction
Novel insights on the importance of dietary sodium reduction
AHA 2023
Novel insights on the importance of dietary sodium reduction
- Deepak Gupta, MD